Brought to you by 
AZ gets rights to two of Nektar's candidates
27 Feb 2020
Executive Summary
Drug delivery company Nektar Therapeutics has granted AstraZeneca exclusive worldwide development, manufacturing, and commercialization rights to two drug candidates for opioid-induced constipation (OIC) and pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ gets rights to two of Nektar's candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice